	TH AND HUMAN SERVICES G ADMINISTRATION
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
555 Winderley Place, Suite 200	1/9/2019-1/23/2019*
Maitland, FL 32751	FEI NUMBER
(407) 475-4700 Fax: (407) 475-4768	3010922197
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	•
Gregory G. Gaiser, Owner and CEO	
FIRM NAME	STREET ADDRESS
Complete Pharmacy and Medical Solutions,	5829 NW 158th St
LLC dba Complete Pharmaceutics	
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Miami Lakes, FL 33014-6721	Outsourcing Facility

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM I OBSERVED:

OBSERVATION 1

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, your firm failed to perform and document investigations for stability failures for the following drug products:

- Atropine Sulfate 0.4mg/mL (b) (4) syringe, Lot 33226/H: Accelerated testing documented a potency of 108% and room temperature testing documented a potency of 107.8% (specifications (b) (4)) at day 8.
- Epinephrine 0.1mg/mL (b) (4) syringe, Lot 34523/C: Accelerated testing documented a potency of 89.2 % at 31 days and 79.9% at 48 days (specification (b) (4)).
- Succinylcholine Chloride PF (b) (4) 20mg/mL syringe, Lot 32995/C: Accelerated testing documented a potency of 79.7% (specification (b) (4)) at day 63.

OBSERVATION 2

PREVIOUS EDITION OBSOLETE

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.

Specifically, your firm does not perform potency testing prior to release for out of

SEE REVERSE OF THIS PAGE	Jennifer L Huntington,	Investigator	Jennifer L, Huntington Investigation Sympol by Jenn fer L. Huntington Sympol by Jenn fer L. Huntington X. Dafe Signed 01-23-2019 07 12 21	1/23/2019
FORM FDA 483 (09/08)	PREVIOUS EDITION ORSOLETE	INSPECTIONAL OBSERVATIO	NIC .	PAGE 1 of 5 PAGES

INSPECTIONAL OBSERVATIONS

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION			
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION		
555 Winderley Place, Suite 200	1/9/2019-1/23/2019*		
Maitland, FL 32751	FEI NUMBER		
(407) 475-4700 Fax: (407) 475-4768	3010922197		
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	•		
Gregory G. Gaiser, Owner and CEO			
FIRM NAME	STREET ADDRESS		
Complete Pharmacy and Medical Solutions,	5829 NW 158th St		
LLC dba Complete Pharmaceutics			
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED		
Miami Lakes, FL 33014-6721	Outsourcing Facility		

formulations and out of one non-sterile drug formulations. Examples include, but are not limited to the following sterile and non-sterile drug products:

- Hydroxocobalamin 1000 mcg/mL injectable, Lot 35710/B, BUD 08/30/19
- Testosterone Cypionate 200 mg/mL injectable, Lot 35031/C, BUD 04/27/19
- HCG 5,000 IU (b) (4) Lot 32410, BUD 03/30/19
- Cholecalciferol 50,000 IU #2476, Lot 32485/B, BUD 04/16/19
- L-asparaginase 10,000 IU, Lot 34417, BUD 03/11/19
- Hydroquinone/Fluocinolone/Tretinoin 4%/0.01%/0.05% cream, Lot 33672, BUD 09/29/18
- HCG ODT (b) (4) 1,000 IU tablet, Lot 36034, BUD 01/08/20
- Tadalafil 20MG/GM (b) (4) (Crème de Menthe) troche, Lot 35966, BUD 06/02/19
- Naltrexone (b) (4)4.5MG capsule, Lot 35951, BUD 07/01/19
- Progesterone/Pregnenolone/DHEA 260MG/20MG/5MG, Lot 35989, BUD 05/04/19

OBSERVATION 3

Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.

Specifically, your firm has failed to perform stability testing on out of out o

Hydroxocobalamin 1000 mcg/mL injectable, Lot 35710/B, BUD 08/30/19 (330 days)

SEE REVERSE OF THIS PAGE	- [[[[[[[[[[[[[[[[[[[Investigator	Jenniter L Huntington Investigation Signed By Jenniter L Huntington X Date Signed 01-23-2019 07 12 21	DATE ISSUED 1/23/2019
FORM FDA 483 (00/08)	DREWING EDITION OPEN ETE	INSPECTIONAL OBSERVATION	ONS	PAGE 2 of 5 PAGES

	TH AND HUMAN SERVICES GADMINISTRATION
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
555 Winderley Place, Suite 200	1/9/2019-1/23/2019*
Maitland, FL 32751 (407) 475-4700 Fax: (407) 475-4768	FEI NUMBER 3010922197
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	
Gregory G. Gaiser, Owner and CEO	
FIRM NAME	STREET ADDRESS
Complete Pharmacy and Medical Solutions, LLC dba Complete Pharmaceutics	5829 NW 158th St
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Miami Lakes, FL 33014-6721	Outsourcing Facility

- Testosterone Cypionate 200 mg/mL injectable, Lot 35031/C, BUD 04/27/19 (180 days)
- HCG 5,000 IU (b) (4) Lot 32410, BUD 03/30/19 (330 days)
- Cholecalciferol 50,000 IU #2476, Lot 32485/B, BUD 04/16/19 (330 days)
- L-asparaginase 10,000 IU, Lot 34417, BUD 03/11/19 (180 days)
- HCG ODT (b) (4) 1,000 IU tablet, Lot 36034, BUD 01/08/20 (365 days)
- Methionine (b) (4) Lot 33685/B, BUD 04/20/19 (330 days)

OBSERVATION 4

Specific identification tests are not conducted on components that have been accepted based on the supplier's report of analysis.

Specifically, your firm does not perform identity testing on any lot of active drug ingredient used in the production of drug products.

OBSERVATION 5

OBSERVATION 6

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

The results of the examination of the packaged and labeled products were not documented in the batch production or control records.

Specifically, your firm has no evidence that you perform visual inspections of your sterile drug products after labeling and prior to release for distribution. For example, your firm does not document visual inspections of finished, labeled drug products nor does your firm have a procedure describing a visual inspection of finished, labeled drug products prior to release for distribution.

SEE REVERSE OF THIS PAGE EMPLOYEE(S) SIGNATURE Jennifer L Huntington, Investigator Jennifer L Huntington Investigator X Date Signed DI-23-2019 07 12.21

INSPECTIONAL OBSERVATIONS

PAGE 3 of 5 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION			
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION		
555 Winderley Place, Suite 200	1/9/2019-1/23/2019*		
Maitland, FL 32751 (407)475-4700 Fax:(407)475-4768	FEI NUMBER 3010922197		
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	L.		
Gregory G. Gaiser, Owner and CEO			
FIRM NAME	STREET ADDRESS		
Complete Pharmacy and Medical Solutions, LLC dba Complete Pharmaceutics	5829 NW 158th St		
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED		
Miami Lakes, FL 33014-6721	Outsourcing Facility		

Equipment for adequate control over air pressure is not provided when appropriate for the manufacture, processing, packing or holding of a drug product.

Specifically, your firm does not continuously monitor the pressures in your ISO 7 positive pressure and negative pressure clean rooms, ISO 7 ante rooms, and ISO 8 Main Lab.

OBSERVATION 7

Your firm compounds drugs that are essentially a copy of one or more approved drugs within the meaning of sections 503B(a)(5) and 503B(d)(2).

Specifically, you compound drug products that:

- a) are identical or nearly identical to an approved drug that is not on the drug shortage list in effect under section 506E at the time of compounding, distribution, and dispensing; or
- b) are not identical or nearly identical to an approved drug but contain a bulk drug substance that is also a component of an approved drug, and for which there is no change that produces for an individual patient a clinical difference, as determined by the prescribing practitioner, between the compounded drug and the comparable approved drug.

Examples of compounded drug products that are essentially a copy of one or more approved drugs include:

SEE REVERSE OF THIS PAGE	Jennifer L Huntington,	Investigator	Jenniter I. Hurtington Investigation Signed By Jenn fer L. Huntington S. Date Signed b1-23-2019 07 12 21	1/23/2019
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATION	ONS	PAGE 4 of 5 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION			
555 Winderley Place, Suite 200	1/9/2019-1/23/2019*			
Maitland, FL 32751 (407)475-4700 Fax: (407)475-4768	FEI NUMBER 3010922197			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	'			
Gregory G. Gaiser, Owner and CEO				
FIRM NAME	STREET ADDRESS			
Complete Pharmacy and Medical Solutions, LLC dba Complete Pharmaceutics	5829 NW 158th St			
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED			
Miami Lakes, FL 33014-6721	Outsourcing Facility			

- Hydroxocobalamin 1000 mcg/mL injectable, Lot 35710/B, BUD 08/30/19
- Hydroquinone/Fluocinolone/Tretinoin 4%/0.01%/0.05% cream, Lot 33672, BUD 09/29/18
- Testosterone Cypionate 200 mg/mL injectable, Lot 35031/C, BUD 04/27/19

*DATES OF INSPECTION

1/09/2019(Wed), 1/10/2019(Thu), 1/11/2019(Fri), 1/14/2019(Mon), 1/16/2019(Wed), 1/22/2019(Tue), 1/23/2019(Wed)

SEE REVERSE OF THIS PAGE		, Investigator	Jennifer L Huntington Investigation Signed By Jenn fer L Huntington X Date Signed 01-23-2019 07 12 21	DATE ISSUED 1/23/2019
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVAT	IONS	PAGE 5 of 5 PAGES